Physician profile
Peyton E Goodie
NPI 1780113829
$2,211.76
in general payments reported to CMS, 2019-2025
20 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $39.61 · 2023: $45.10 · 2024: $769 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.99 |
| Education | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $503.84 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $421.25 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $274.18 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $246.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $117.25 | 2021-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $106.32 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $92.56 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $87.47 | 2024-2025 | |
| Biofrontera INC. | $54.93 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $52.18 | 2025 | Klisyri |
| Amgen INC. | $50.92 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $46.54 | 2025 | Opzelura |
| Botanix Sb INC | $41.27 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $24.98 | 2024 | Aklief |
| Leo Pharma INC. | $22.75 | 2024 | Adbry |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $20.59 | 2025 | Affinity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2025 | Spevigo |
| Nabriva Therapeutics, Plc | $14.47 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.42 | 2021 | |
| Mayne Pharma Commercial LLC | $3.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Goodie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.